Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023 May 04, 2023
Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H Apr 24, 2023
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol Apr 17, 2023
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Mar 31, 2023
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Mar 30, 2023
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights Mar 30, 2023
